Cavion Raises $26.1 MM Series A Financing | January 06, 2017
Financing will support development of novel treatments for neurological diseases
Cavion to Present Clinical Trial Preliminary Results at ASTRO | September 26, 2016
Yale studies the combination of Cavion’s T-type calcium channel blocker mibefradil with hypofractionated radiation
Cavion Names Senior Scientific and Business Advisors | February 01, 2016
Llinas and Lynch Bring Decades of Neuroscience and Strategic Insight to Company
Cavion to Deliver Three Presentations at SNO, the World's Leading Multidisciplinary Brain Cancer Conference | November 19, 2015
Data Suggests Cavion's T-type Calcium Channel Blocker Mibefradil is Effective Against Glioblastoma
Cavion LLC Closes $5M Round of Convertible Debt | November 10, 2015
Financing Will Support Platform Development
Show More

Contact Us